Pharmaceutical Technology17m
ENB-105 by Ennovabio for Inflammatory Bowel Disease: Likelihood of Approval
ENB-105 is under development for the treatment of inflammatory bowel disease and immune checkpoint inhibitor colitis (ICI-Colitis). It is being developed based on eSTEM systems biology platform.
Pharmaceutical Technology51m
Vebeglogene autotemcel by Lantu Biopharma for Beta Thalassaemia: Likelihood of Approval
Vebeglogene autotemcel is under clinical development by Lantu Biopharma and currently in Phase II for Beta Thalassaemia.
Pharmaceutical Technology51m
XB-010 by Exelixis for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval
XB-010 is under clinical development by Exelixis and currently in Phase I for Triple-Negative Breast Cancer (TNBC).
Pharmaceutical Technology53m
CLN-619 by Cullinan Therapeutics for Refractory Multiple Myeloma: Likelihood of Approval
CLN-619 is under clinical development by Cullinan Therapeutics and currently in Phase I for Refractory Multiple Myeloma.
Pharmaceutical Technology51m
20ND02 by HK inno.N for Glaucoma: Likelihood of Approval
ND02 is under clinical development by HK inno.N and currently in Phase II for Glaucoma. According to GlobalData, Phase II drugs for Glaucoma have a 39% phase transition success rate (PTSR) indication ...